Europe Overactive Bladder Treatment Market

Europe Overactive Bladder Treatment Market Size (2023 To 2028)

The Europe overactive bladder treatment market size was valued at USD 0.96 billion in 2022 and is projected to grow at a CAGR of 3.2% from 2023 to 2028 and be worth USD 1.12 billion by 2028.

The growing patient population suffering from the overactive bladder in the European region propels the European market growth. An estimated 17% of the European population aged above 40 years of age are suffering from overactive bladder. Women are more affected by this disorder. Mostly, older people suffer from enlarged prostate and diabetes, resulting in bladder function issues. Some physical movements or activities that put pressure on the urinary bladder are coughing, sneezing, laughing, and exercising. Therefore, the population prefers overactive bladder treatment through oral capsules and injections.

The increasing development of novel drugs and treatments for overactive bladder disorders is another factor boosting the European overactive bladder treatment market. The governments of European countries have conducted numerous surveys on the population suffering from overactive bladder disorder and their treatment. The data populated has been handed over to the researchers to focus on developing new drugs that can effectively help reduce urinary infections and urgent urine problems.

In addition, the growing investments from the European governments and the presence of favorable reimbursement policies in the European region are expected to fuel the growth rate of the European market. The rising prevalence of Parkinson's disease in the European region led to the development of overactive bladder disorder, which is estimated to propel the growth of the overactive bladder treatment market in Europe. Parkinson's disease is a type of brain disorder that results in uncontrolled movements such as shaking, stiffness, and urgency during urination. The nervous system controls all the nerves in the body. As a result, these people also choose overactive balder treatment to stop the unnecessary urinary flow.

However, side effects associated with overactive bladder drugs as part of the treatment procedure are one of the major factors hampering the regional market growth. Common side effects are dry mount, dry eyes, constipation, and others. In addition, poor drug awareness levels are another factor hindering market growth. Furthermore, the unavailability of the drugs in every medical store, negligence of the disorder among the population, and a long time for the approval of the drugs are the other factors that impede the market growth.

This research report on the Europe overactive bladder treatment market has been segmented and sub-segmented into the following categories:

By Treatment:

• Mirabegron
• Anticholinergics
• Botox
• Intravesical Instillation
• Neurostimulation

By Disease:

• Neurogenic Overactive Bladder
• Idiopathic Overactive Bladder

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The Europe overactive bladder treatment market had a substantial share of the worldwide market in 2022 and is estimated to witness a healthy CAGR during the forecast period owing to the increasing awareness of available treatment options and increasing healthcare expenditure. In addition, an increasing number of product approvals is expected to aid the regional market growth during the forecast period. For instance, Dysport gained approval from the European government for managing urine incontinence in adults suffering from neurogenic detrusor overactivity. This is released in the form of an injection manufactured by Ipsen.

The UK market is anticipated to capture the largest share of the Europe overactive bladder treatment market during the forecast period. An estimated 12% of the total adult population in the UK suffers from overactive bladder disorder. Some of the causes of overactive bladder are weak of pelvic muscles, nerve damage due to stroke, and side effects of medication, alcohol, and smoking. One in six women in the United Kingdom suffers from overactive bladder disorder.

The German market in the European region is projected to witness a healthy CAGR in the coming years owing to the increasing number of clinical trial centers in Germany. In addition, owing to the clinal center's presence, many local researchers are focusing on developing oral drugs for all age groups to relieve the overactive bladder disorder issue at an affordable price for all types of people. In addition, several measures have been taken by the government to approve the medicine for the population's safety.

KEY MARKET PLAYERS

Pfizer, Allergan Plc, Hisamitsu Pharmaceutical, Johnson & Johnson, Astellas Pharma Inc, Teva Pharmaceutical Industries, Mylan N.V, Sanofi, Aurobindo Pharma Ltd, and Endo International are some of the noteworthy companies in the European overactive bladder treatment market.